Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + gimeracil + nab-paclitaxel + oteracil + oxaliplatin + tegafur
- Development stage
- Unknown
- Lead developer
- Harbin Medical University Cancer Hospital
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
The combination of gemcitabine, gimeracil, nab-paclitaxel, oteracil, oxaliplatin, and tegafur is a multi-agent chemotherapy regimen primarily investigated for the treatment of locally advanced or metastatic pancreatic cancer. This regimen, often referred to as GS-Nab-Ox, integrates four distinct cytotoxic strategies: gemcitabine (a nucleoside analog), S-1 (an oral fluoropyrimidine combination consisting of tegafur, gimeracil, and oteracil), nab-paclitaxel (an albumin-bound nanoparticle formulation of paclitaxel), and oxaliplatin (a platinum-based antineoplastic agent). The regimen is designed to leverage the synergistic effects of these agents to inhibit DNA synthesis, induce DNA cross-linking, and disrupt microtubule dynamics, thereby overcoming drug resistance and improving survival outcomes in patients with pancreatic adenocarcinoma. It is being developed and studied by the Affiliated Cancer Hospital of Harbin Medical University.
- Other names
- Gemcitabine + S-1 + nab-paclitaxel + oxaliplatinGS-Nab-Ox regimen
02
Targets
RNR (Ribonucleotide reductase)TS (Thymidylate synthase)DNATUBB (Tubulin (alpha and beta subunits))OPRT (Orotidine 5'-phosphate decarboxylase)DPYD (Dihydropyrimidine dehydrogenase)
Beyond the preview
Go deeper on gemcitabine + gimeracil + nab-paclitaxel + oteracil + oxaliplatin + tegafur.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + gimeracil + nab-paclitaxel + oteracil + oxaliplatin + tegafur.